![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The financing will be utilized to fund the progress of the company’s primary candidate, RLS-1496, for treating patients with atopic dermatitis and chronic psoriasis.
Lead Product(s): RLS-1496
Therapeutic Area: Dermatology Product Name: RLS-1496
Highest Development Status: IND Enabling Product Type: Small molecule
Recipient: Rubedo Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 22, 2024